Fisher Asset Management LLC Boosts Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Fisher Asset Management LLC increased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 176,637 shares of the medical research company's stock after purchasing an additional 53,735 shares during the quarter. Fisher Asset Management LLC owned 0.10% of Exact Sciences worth $9,925,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after purchasing an additional 7,873 shares during the period. Champlain Investment Partners LLC raised its position in Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock worth $169,924,000 after purchasing an additional 245,980 shares during the period. Bellevue Group AG increased its position in shares of Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock valued at $98,738,000 after acquiring an additional 290,585 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Exact Sciences by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company's stock valued at $88,017,000 after acquiring an additional 45,015 shares during the period. Finally, Groupama Asset Managment purchased a new position in shares of Exact Sciences in the third quarter valued at about $821,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Remove Ads

Exact Sciences Stock Up 0.9 %

NASDAQ:EXAS traded up $0.42 during mid-day trading on Friday, hitting $47.06. 2,374,666 shares of the company's stock were exchanged, compared to its average volume of 2,348,845. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The business has a fifty day moving average price of $53.09 and a 200 day moving average price of $59.43. The company has a market cap of $8.74 billion, a PE ratio of -8.45 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Analyst Ratings Changes

EXAS has been the topic of a number of analyst reports. Piper Sandler decreased their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Benchmark restated a "buy" rating and issued a $65.00 price objective on shares of Exact Sciences in a research report on Monday, January 13th. William Blair restated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. TD Cowen boosted their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Finally, Barclays decreased their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $71.94.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.